-
-
-
-
-
-
-
PTC Therapeutics reports Q4 Sephience revenue of $92.5 million
-
-
-
-
-
-
-
Where can biotech stocks go from here? RBC answers
-
-
-
-
-
-
-
Goldman Sachs Reiterates Sell Rating on PTC Therapeutics (PTCT)
-
-
-
-
-
-
-
PTC Therapeutics (PTCT) PT Raised to $63 at RBC Capital
-
-
-
-
-
-
-
PTC Therapeutics (PTCT) to Resume Trading at 4:50 p.m.
-
-
-
-
-
-
-
Citi Reiterates Neutral Rating on PTC Therapeutics (PTCT)
-
-
-
-
-
-
-
PTC Therapeutics (PTCT) reported revenue at $190 million, provides guidance
-
353,174 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

